Zhaoyan New Drug said its stock rose sharply over three straight trading days from July 14 to July 16, 2026, with the cumulative deviation in closing-price gains exceeding 20%. According to Jin10, the company warned that short-term gains had been large, market sentiment may be overheated, and irrational speculation risk remained high, with the stock facing a risk of decline at any time. The company also said the fair value of its biological assets was affected by multiple uncertainties and carried a significant risk of value fluctuations.